This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Dec 7;7(12):657.

doi: 10.1038/nrneurol.2011.183.

Alzheimer disease: Amyloid-targeting antibody performs well in phase II trial

PMID: 22146778
DOI: 10.1038/nrneurol.2011.183

Comment

Alzheimer disease: Amyloid-targeting antibody performs well in phase II trial

Katie Kingwell. Nat Rev Neurol. 2011.

. 2011 Dec 7;7(12):657.

doi: 10.1038/nrneurol.2011.183.

Author

PMID: 22146778
DOI: 10.1038/nrneurol.2011.183

No abstract available

PubMed Disclaimer

Comment on

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.
Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L. Ostrowitzki S, et al. Arch Neurol. 2012 Feb;69(2):198-207. doi: 10.1001/archneurol.2011.1538. Epub 2011 Oct 10. Arch Neurol. 2012. PMID: 21987394 Clinical Trial.

References

1. Arch Neurol. 2012 Feb;69(2):198-207 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.